{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jassi C"],"funding":["Ministry of Science and Technology, Taiwan","China Medical University, Taiwan","Buddhist Tzu Chi Medical Foundation","Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation"],"pagination":["102125"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11456798"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50"],"pubmed_abstract":["Colorectal cancer (CRC) remains the third most prevalent type of cancer worldwide contributing to an estimated 10 % of all cancer cases. CPT-11 is one of the first-line drugs for CRC treatment. Unfortunately, the development of drug resistance significantly exacerbates the adverse impact of CRC. Consequent tumor recurrences and metastasis, years after treatment are the frequently reported incidences. MicroRNAs (miRNA) are short non-coding RNA with the functionality of gene suppression. The insulin-like growth factor type 1 receptor (IGF1R) is a tyrosine kinase receptor frequently upregulated in cancers and is associated with cell survival and drug resistance. MiRNAs are frequently reported to be dysregulated in cancers including CRC. Evidence suggests that dysregulated miRNAs have direct c"],"journal":["Translational oncology"],"pubmed_title":["MicroRNA-376a-3p sensitizes CPT-11-resistant colorectal cancer by enhancing apoptosis and reversing the epithelial-to-mesenchymal transition (EMT) through the IGF1R/PI3K/AKT pathway."],"pmcid":["PMC11456798"],"funding_grant_id":["IMAR-112\\u201301\\u201318","111\\u20132314-B-303"],"pubmed_authors":["Chen MC","Kuo WW","Ho TJ","Jassi C","Hsieh DJ","Huang CY","Li CC","Wang TF","Chang YC","Kuo CH"],"additional_accession":[]},"is_claimable":false,"name":"MicroRNA-376a-3p sensitizes CPT-11-resistant colorectal cancer by enhancing apoptosis and reversing the epithelial-to-mesenchymal transition (EMT) through the IGF1R/PI3K/AKT pathway.","description":"Colorectal cancer (CRC) remains the third most prevalent type of cancer worldwide contributing to an estimated 10 % of all cancer cases. CPT-11 is one of the first-line drugs for CRC treatment. Unfortunately, the development of drug resistance significantly exacerbates the adverse impact of CRC. Consequent tumor recurrences and metastasis, years after treatment are the frequently reported incidences. MicroRNAs (miRNA) are short non-coding RNA with the functionality of gene suppression. The insulin-like growth factor type 1 receptor (IGF1R) is a tyrosine kinase receptor frequently upregulated in cancers and is associated with cell survival and drug resistance. MiRNAs are frequently reported to be dysregulated in cancers including CRC. Evidence suggests that dysregulated miRNAs have direct c","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-09T07:15:46.2Z","creation":"2025-04-04T02:30:57.033Z"},"accession":"S-EPMC11456798","cross_references":{"pubmed":["39317064"],"doi":["10.1016/j.tranon.2024.102125"]}}